Brief: BioVaxys Enters Agreement With Inotiv For Preclinical Studies Of Its Covid-T Immunodiagnostic Program
18/03/2021 12:15
March 18 (Reuters) - Biovaxys Technology Corp BIOV.CD :
* BIOVAXYS ENTERS AGREEMENT WITH INOTIV TO CONDUCT
PRECLINICAL
TOXICITY STUDIES FOR ITS COVID-T™ IMMUNODIAGNOSTIC PROGRAM
* BIOVAXYS TECHNOLOGY CORP - ANTICIPATES THAT PRECLINICAL
TOXICITY
STUDY RESULTS WILL BE AVAILABLE EARLY SUMMER
* BIOVAXYS TECHNOLOGY CORP - INTENDS TO SUBMIT ITS PRE-IND
MEETING
REQUEST TO FDA FOR COVID-T EARLY NEXT MONTH
Source text for Eikon: ID:nCNW6fQrxa
Further company coverage: BIOV.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biovaxys Technology
See all newsBrief: Biovaxys Appoints Former Sanofi Vaccines Executive To Board Of Directors
Brief: Biovaxys Announces Life Offering
Brief: Biovaxys And Horizon Technology Finance Execute Amendment To Asset Purchase Agreement
Brief: Biovaxys And Horizon Technology Finance Execute Amendment To Asset Purchase Agreement
Brief: Biovaxys Announces Consolidation And Concurrent Brokered Private Placement Offering For Gross Proceeds Of Up To $3,000,000